Skip to content

Brain Manganese Deposition in High Risk Neonates

Brain Manganese Deposition in High Risk Neonates

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00392977
Enrollment
43
Registered
2006-10-26
Start date
2006-08-31
Completion date
2010-12-31
Last updated
2013-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholestasis, Digestive System Abnormalities, Necrotizing Enterocolitis

Keywords

Manganese, Neonatal Intensive Care, MRI, Parenteral Nutrition, Prematurity

Brief summary

Excessive exposure to manganese (Mn) results in Mn deposition in the brain causing adverse neurological effects. Sick infants requiring parenteral nutrition (PN) may be at increased risk of Mn neurotoxicity because neonatal PN solutions contain high concentrations of Mn. This proposal will investigate brain deposition of Mn, a paramagnetic element, by magnetic resonance (MR) imaging in preterm and term neonates receiving Mn-supplemented PN and gestational age-matched control infants. The goals of this project are to identify neonatal populations that are at increased risk of excessive brain Mn deposition based on their gestational age, iron status, hepatic function and dietary Mn intake, and to make evidence-based recommendations for appropriate Mn supplementation and monitoring of infants receiving PN.

Detailed description

Manganese (Mn) is an essential metal needed for normal growth and development. Excessive environmental or dietary exposure results in Mn deposition in Mn-sensitive brain regions causing adverse psychological and neurological effects. Sick infants requiring parenteral nutrition (PN) may be at increased risk of Mn neurotoxicity because neonatal PN solutions contain high concentrations of Mn, PN bypasses the normal intestinal absorptive control and biliary excretory mechanisms for Mn, and infants are at a critical stage of brain development. Furthermore, iron (Fe) deficiency, a common problem among sick neonates, increases Mn brain uptake because Mn and Fe compete for the same carrier transport systems in the central nervous system. This proposal will investigate brain deposition of Mn, a paramagnetic element, by magnetic resonance (MR) imaging in 40 neonates receiving Mn-supplemented PN and 10 control infants. Two specific aims will test the following hypotheses: 1. Shortening of MR T1 and T2 relaxation times (a marker for Mn) in Mn-sensitive brain regions in neonates receiving PN will correlate directly with * dietary Mn intake, * days on PN, * blood Mn levels (measured by Inductively Coupled Plasma-Mass Spectrometry) * hepatic dysfunction/cholestasis (assessed by conjugated bilirubin levels). 2. shortening of T1 and T2 relaxation times will correlate inversely with * gestational age * Fe status (assessed by serum Fe, ferritin, transferrin, soluble transferrin receptor and hemoglobin). The potential for increased brain Mn accumulation in infants and the potential health risks associated with elevated brain Mn burden represent crucial, unexplored issues of exposure and susceptibility. The impact of dietary Mn, and especially parenterally delivered dietary Mn, gestational age, Fe status, and hepatic dysfunction on the ability of the neonatal brain to regulate Mn deposition has not been scientifically addressed. The proposed clinical investigation has enormous health significance and may shed light on the development and progression of neurological dysfunction in infants and children on prolonged parenteral nutrition.

Interventions

trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.

Sponsors

National Institute of Environmental Health Sciences (NIEHS)
CollaboratorNIH
Vanderbilt University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Days to 12 Months
Healthy volunteers
No

Inclusion criteria

1. Greater than 30 days postnatal age 2. In the preceding four weeks have received \>75% of their nutrition as Mn-supplemented PN 3. Clinically stable for transport to the MR facility 4. Signed parental consent.

Exclusion criteria

1. Any infant not expected to survive to the age of 3 months or 2. Not expected to achieve sufficient clinical stability to tolerate the MRI procedure.

Design outcomes

Primary

MeasureTime frame
Correlation between changes in MR signals and dietary Mn intake, number of days on PN and blood Mn levelsat hospital discharge and 6 months of age

Secondary

MeasureTime frame
Comparison of pallidal-white matter T1 ratios and absolute T1 and T2 values in control infants and neonates receiving Mn-supplemented PN.at hospital discharge and at 6 months of age

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026